Adverse events of nusinersen: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database

Nusinersen, the initial FDA-approved medication, treats Spinal Muscular Atrophy. This study utilized the FDA's adverse event reporting system (FAERS) database to examine, evaluate, and provide substantiation for the safety of Nusinersen to assist in clinical decision-making.